SOLAR-1: alpelisib plus fulvestrant for PIK3CA-mutated hormone receptor-positive advanced breast cancer
Alpelisib, a pill blocking the mutated PI3K-alpha enzyme, nearly doubled the time to progression when added to fulvestrant in advanced breast cancer carrying a PIK3CA mutation, at the cost of high blood sugar and rash.
Overview
Phase 3 placebo-controlled trial of 572 patients with hormone receptor-positive, HER2-negative advanced breast cancer after an aromatase inhibitor, randomised to alpelisib or placebo with fulvestrant, stratified by PIK3CA mutation status.
In the 341 patients with PIK3CA-mutated tumours, median progression-free survival was 11.0 versus 5.7 months (hazard ratio 0.65); no benefit was seen without the mutation. Hyperglycaemia, rash and diarrhoea led to frequent dose changes.
- Median progression-free survival 11.0 vs 5.7 months in PIK3CA-mutated disease; hazard ratio 0.65.
- Grade 3 or worse hyperglycaemia in 36.6 percent of alpelisib patients.
PIK3CA testing became routine in advanced hormone receptor-positive breast cancer, with alpelisib-fulvestrant the first approved PI3K-targeted regimen; capivasertib and inavolisib now offer alternatives.
- Few patients had received a prior CDK4/6 inhibitor.
- Toxicity leads to discontinuation in a meaningful minority.
Similar pages
not linked directly; found by shared links- PersonFabrice André
- TrialStudy to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
Shares Alpelisib, HR-positive metastatic breast cancer after CDK4/6 inhibitors.
- TrialA Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
Shares Alpelisib, HR-positive metastatic breast cancer after CDK4/6 inhibitors.
- Key paperCAPItello-291: capivasertib plus fulvestrant in hormone receptor-positive advanced breast cancer
Shares HR-positive metastatic breast cancer after CDK4/6 inhibitors, New England Journal of Medicine.
- TermPTEN loss
Shares Alpelisib, HR-positive metastatic breast cancer after CDK4/6 inhibitors.
- Key paperDESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer
Shares HR-positive metastatic breast cancer after CDK4/6 inhibitors, New England Journal of Medicine.